We are delighted to have such a skilled and reputable manufacturing partner in Lonza to help us advance our robust research and development programs using AAV to treat macular degeneration and other blinding diseases, said Thomas W. Chalberg, Ph.D., chief executive officer, Avalanche Biotechnologies, Inc.